Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DDO | Q99489 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433567 | 0.91 | HCAR2 (0.63) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL31064103 | 0.91 | HCAR2 (0.63) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL3509681 | 0.89 | MKNK1 (0.47) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL21935429 | 0.89 | MKNK1 (0.47) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL4477190 | 0.89 | MKNK1 (0.66) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL3102318 | 0.85 | HCAR2 (0.69) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL2141359 | 0.85 | CA5A (0.56) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL29730943 | 0.85 | CA5A (0.56) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 | |
| SCHEMBL21607970 | 0.85 | RAF1 (0.48) | MKNK1MKNK2CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL21729381 | 0.85 | MKNK1 (0.45) | MKNK1MKNK2HCAR2CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112608453-B | Pyridine-based D-A type cross conjugated polymer, and preparation and application thereof | 华中科技大学 | 2023-05-12 | — | — | CN | disclosed |
| US-11377556-B2 | Polyimide-based block copolymer and polyimide-based film comprising the same | LG CHEM, LTD. (KR) | 2022-07-05 | — | — | US | disclosed |
| US-20210277235-A1 | POLYIMIDE-BASED BLOCK COPOLYMER AND POLYIMIDE-BASED FILM COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2021-09-09 | — | — | US | disclosed |
| US-9644076-B2 | Cross-linkers for hydrogels, hydrogels including these cross-linkers and applications thereof | Max-Planck-Gesellschaft zur Foerderung der Wissenschafen e. V. (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160051575-A1 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS | OLIVA EUGENE J (US) | 2016-02-25 | — | — | US | disclosed |
| US-9173889-B2 | Heparin-based compositions and methods for the inhibition of metastasis | OLIVA EUGENE J (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150099718-A1 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS | OLIVA EUGENE J (US) | 2015-04-09 | — | — | US | disclosed |
| US-8912167-B2 | Heparin-based compositions and methods for the inhibition of metastasis | DIAMOND, PAUL | 2014-12-16 | — | — | US | disclosed |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-6191234-B1 | CONJUGATED DIENE-AROMATIC VINYL COPOLYMER OBTAINED BY MODIFYING POLYMER WITH A AMINO GROUP IS USED TO IMPROVE WET SKID RESISTANCE, WEAR RESISTANCE OF AUTOMOBILE TIRE TREAD | JSR CORPORATION (JP) | 2001-02-20 | — | — | US | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | MKNK1 2094/4885MKNK2 2603/4885HCAR2 2362/4885 |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | BID, BAD, BIRC3 | MKNK1 588/4885MKNK2 945/4885HCAR2 2915/4885 |
| US-20150099718-A1 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS | HPSE, SERPINC1, CD44 | MKNK1 823/4885MKNK2 671/4885HCAR2 1740/4885 |
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | MKNK1 4037/4885MKNK2 4353/4885HCAR2 300/4885 |
| US-20160051575-A1 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS | HPSE, SERPINC1, CD44 | MKNK1 823/4885MKNK2 671/4885HCAR2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.